A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
第一作者机构:[1]Sichun Canc Hosp, Chengdu, Peoples R China
推荐引用方式(GB/T 7714):
Hong Huangming,Zhang Mingzhi,Peng Zhigang,et al.A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma[J].BLOOD.2023,142:doi:10.1182/blood-2023-180372.
APA:
Hong, Huangming,Zhang, Mingzhi,Peng, Zhigang,Shen, Jianzhen,Shuang, Yuerong...&Lin, Tongyu.(2023).A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma.BLOOD,142,
MLA:
Hong, Huangming,et al."A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma".BLOOD 142.(2023)